ReviewJournal of blood medicine2017
Reversing factor Xa inhibitors - clinical utility of andexanet alfa.
Review in Journal of blood medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Anticoagulants, Their Laboratory Monitoring, and Reversal.Hematology reports · 2026Review
- Procoagulant off-target effect of the direct oral anticoagulant reversal agent Andexanet alfa.Blood vessels, thrombosis & hemostasis · 2025Article
- Principles of reversal of anticoagulation in patients with intracerebral hemorrhage related to oral anticoagulants.European stroke journal · 2025Review
- Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine).British journal of clinical pharmacology · 2025Review
- Urgent Reversal of Direct Oral Anticoagulants in Critical and Life-Threatening Bleeding: A Multidisciplinary Expert Consensus.Journal of clinical medicine · 2024Review
- Clinical Care Pathway and Management of Major Bleeding Associated with Nonvitamin K Antagonist Oral Anticoagulants: A Modified Delphi Consensus from Saudi Arabia and UAE.Mediterranean journal of hematology and infectious diseases · 2024Review
- A Rare Case of Apixaban-Induced Subdural Hematoma in Elderly Heart Failure Patient.International medical case reports journal · 2023Article
- Post-Acute COVID-19 Syndrome for Anesthesiologists: A Narrative Review and a Pragmatic Approach to Clinical Care.Journal of cardiothoracic and vascular anesthesia · 2022Review
- Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200.Journal of thrombosis and haemostasis : JTH · 2020Article
- Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.Medicines (Basel, Switzerland) · 2019Review
- The death of aspirin for primary prevention-should aspirin be changed to a prescription only medication?Annals of translational medicine · 2019Article
- Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.Therapeutic advances in drug safety · 2019Review
- Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits.Journal of thrombosis and thrombolysis · 2019Article
- Coagulation Factor Xa (Recombinant), Inactivated-zhzo (Andexanet Alfa).Hospital pharmacy · 2018Review
- Andexanet Alfa: First Global Approval.Drugs · 2018Review
- Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome.Kidney international reports · 2018Review
- Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA.Drugs & therapy perspectives : for rational drug selection and use · 2018Article
- Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
- Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet to be licensed. Unlike the strategy to reverse the only oral direct thrombin inhibitor with idarucizumab, which is a humanized monoclonal antibody fragment, a different approach is necessary to design a single agent that can reverse multiple anti-FXa medications. Andexanet alfa is a FXa decoy designed to reverse all anticoagulants that act through this part of the coagulation cascade including anti-FXa DOACs, such as apixaban, edoxaban and rivaroxaban, and indirect FXa inhibitors such as low-molecular-weight heparins. This narrative reviews the development of andexanet alfa and explores its basic science, pharmacokinetics/pharmacodynamics, animal models, and human studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.